# DISCOVERY SERIES
Conference Schedule 2023

Automation in Discovery Symposium

Virtual Symposium	1-Day Event

- A thorough one-day symposium addressing emerging and enabling automation technologies and platforms in drug discovery to reduce drug attrition and improve productivity
- This in-depth symposium will feature valuable case studies in automation: improve screening for target validation & hit finding; accelerate drug formulation & delivery; and optimise of drug design
- Bringing together leading international pharma and biotech companies for discussion, knowledge-sharing and focused networking to advance drug discovery processes

February 2023
GMT (UTC+0)

Organ Modelling UK:
IN-PERSON

In-Person Congress & Exhibition *(Supported Digitally)*	2-Day Event

- 300+ attendees & 40+ presentations
- Discover the latest tools and strategies for advanced organ model development. Featuring key case studies on the application of organoid and organ-on-a-chip models in disease modelling, drug discovery and predictive diagnostics
- From exploratory techniques through to proven preclinical methods, benefit from the expertise of leading academic, pharmaceutical, and solution-oriented speakers, sharing the latest developments for the creation of complex, scalable organ models

April 2023
London, UK

Discovery Europe:
IN-PERSON

In-Person Congress & Exhibition *(Supported Digitally)*	2-Day Event

- 500+ attendees & 60+ presentations
- Explore the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit
- The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimisation
- A plethora of interactive panel and roundtable discussions, with ample networking opportunities to meet and discuss with world leading drug discovery experts

June 2023
Berlin, Germany

Neuroscience Drug Development Europe:
IN-PERSON

In-Person Congress & Exhibition *(Supported Digitally)*	2-Day Event

- 300+ attendees & 15+ presentations
- A thorough 2 day event addressing emerging strategies for the drug development of Neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative and neuropsychiatric diseases.
- This in-depth event will detail the journey of neuroscience discovery from initial lead through to clinical trials, bringing together leading companies for discussion, knowledge-sharing and focused networking
- Co-located with Drug Discovery Summit and Drug Design and Medicinal Chemistry Summit

June 2023
Berlin, Germany

Discovery US:
IN-PERSON

In-Person Congress & Exhibition *(Supported Digitally)*	2-Day Event

- 500+ attendees & 60+ presentations
- Explore the latest advancements in phenotypic and target-based discovery, chemical biology as well as drug design at our two-day summit
- The event will bring together leading experts in the fields of Organoid Discovery, Phenotypic Screening, Targeted Protein Degradation, AI Computational Drug Design and Lead Optimisation
- A plethora of interactive panel and roundtable discussions, with ample networking opportunities to meet and discuss with world leading drug discovery experts

November 2023
Boston, USA

JAN   FEB   MAR   APR   MAY   JUN   JUL   AUG   SEP   OCT   NOV   DEC

Automation in Discovery Symposium
February 2023 | GMT (UTC+0)

- **1-day Event**
- **Virtual Symposium**

Our Automation in Discovery Symposium will host over 300 key leaders and influencers from global pharmaceutical organisations and leading academic research institutions presenting on the latest developments and critical approaches and technologies in automation to reduce attrition and improve productivity in drug discovery.

Agenda at a Glance

Automation In Discovery Symposium

Morning Sessions:
- The Use of Automation of screening in hit finding
- Approaches in HTS, Fragment and DEL based screening
- Automation in Formulation and Delivery

Afternoon Sessions:
- Efficient Combination Of Machine Learning And Automation To Accelerate DMTA Cycles
- Innovating the Chemistry Lab Bench
- Automation In The Organic Chemistry Laboratory

Benefits to Attending

☑ **Examine the latest advancements** and emerging trends in automated systems for drug development and production to aid high-throughput analysis

☑ **Discuss the pioneering innovations** increasing efficiency in the laboratory, and speeding up drug discovery and drug formulation/ delivery processes

☑ **Understand the opportunities** into the integration of automation and new challenges that need to be considered

☑ **Identify opportunities to automate processes** in the Organic Chemistry lab for drug design

How It Works

The Swapcard Platform

Our Symposiums are delivered through Swapcard, our market-leading and highly interactive digital event platform. Alongside the live programme, it has a variety of other features to maximise your event experience, including AI-assisted match-making with other delegates, additional resource such as white papers, exhibitor pages allowing you to connect with leading solution providers and a host of On-Demand content.

Interactivity

Our digital symposiums are designed to maximise interactivity. Each event features panel discussions facilitated by our expert speakers, and you can also join us for our live Q&As where a panel of speakers are ready to answer any questions you may have. The platform further increases your interactions with other attendees by making it simple to connect, chat, share files and more.

Organ Modelling UK: In-Person
April 2023 | London, UK

- **2-day Event**
- **In-Person Congress & Exhibition**
  (Supported Digitally)

Our Organ Modelling Congress addresses an important and expanding field which provides new understandings in organ functionality and novel approaches to drug development. These engineered human organs using Organ-on-a-Chip, Tissue-on-a-Chip & Organoids are a remarkable tool with the potential to facilitate studies that better predict drug efficacy and thereby reduce cost, time, and failure rates in clinical trials. Further, patient-derived organoids hold promise for personalised medicine, as they have the potential to produce individualised predictions of drug response.

Agenda at a Glance

Organ Modelling UK	
Day One	**Day Two**
Track 1: Organoid Development	**Track 1: Organoid Applications**

Track 1: Organoid Development

- Organoid development for disease modelling, drug discovery and predictive diagnostics
- Implications on 3D-cell based screening methods and data management
- Self-assembly vs. template-driven assembly of organoids
- Multi-tissue models
- Scale-up, bioprinting & automated workflows

Track 2: Tissue Chip Application

- Application of tissue-chip technology in drug screening, toxicity and efficacy testing, disease modelling, and personalized medicine
- Organ-on-a-chip and tissue-on-a-chip to mimic in vitro organ structure
- Lung-on-a-chip, brain-on-a-chip, gut-on-a-chip, marrow-on-a-chip, bone-on-a-chip, nerve-on-a-chip

Track 1: Organoid Applications

- Application of organoid techniques in drug screening, hit identification and lead optimisation
- Accelerating the adoption of organoid models in preclinical research
- Exploratory Showcase
  » Immune cell modelling
  » Oncology models
  » Gut microbiome modelling

Track 2: Tissue Chip Development

- Microfluidics and next gen technologies for the creation of in vitro systems
- Overcoming challenges in complexity, robustness and reproducibility
- Challenges to the adoption of tissue-chips in the pharmaceutical industry
- Multi-tissue models

Who will be there?

300+ VPs, Directors & Senior Managers from leading pharma & biotech companies and academic institutions in the following fields and more

- Disease Modelling
- Cell Culture
- Organoid Development
- Organ-on-a-chip
- Toxicology
- Complex in vitro Models
- Drug Discovery
- Regulatory
- Microfluidics
- Disease Modelling
- Cell Technology
- 3D Cell Culture

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Screening Solutions
- 3D Cell Culture Products
- 3D Platforms
- Organ-On-A-Chip
- Technologies
- Human Cells & Tissues
- Drug Development
- Imaging Solutions
- Microfluidics
- Data Management
- Organoid Technologies
- Disease Modelling

Previous year's delegates in numbers:
(From 2020's Discovery Series: Virtual)

FUNCTION
- 39% – Scientist / Academic
- 26% – Manager / Lead
- 23% – Director / Head Professor
- 12% – C-Level

SECTOR
- 52% – Industry
- 25% – Academics
- 23% – Sponsor / Vendor / Commercial

GEOGRAPHY
- 32% – Europe
- 21% – UK
- 20% – US
- 27% – Rest of World

Discovery Europe: In-Person
June 2023 | Berlin, Germany

- **2-day Event**
- **In-Person Congress & Exhibition**
  (Supported Digitally)

Join and network with over 500 industry leaders at the renowned Drug Discovery Summit in Berlin, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling. Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation. Join our 2-day innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.

Agenda at a Glance

Discovery Europe: In-Person	
Pre-Event Workshops: Workshop 1: Organ Modelling Workshop 2: Targeted Protein Degradation Workshop 3: Automation or AI in Medicinal Chemistry and Drug Design	
Drug Discovery Summit	**Drug Design & Medicinal Chemistry Summit**
DAY ONE: Track 1: Identification And Validation Of Novel Targets For Next Generation Therapeutics Track 2: Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery Track 3: Discovery on Target – Screening and Genomic Strategies **DAY TWO:** Track 1: Phenotypic & Target Based Discovery Approaches	**DAY ONE:** Track 1: Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction **DAY TWO:** Track 2: Hit Finding Technologies And Advancements Track 3: Part 1: Automation And Synthesis In Organic Chemistry Part 2: Molecular Drug Design And Med Chem: Innovations In Fragment & Structured Based Drug Discovery

Who will be there?

500+ VPs, Directors & Senior Managers from leading pharma & biotech companies and academic institutions in the following fields and more

- Structure-Based Drug Discovery
- Modelling and Simulation
- Target Validation
- Inhibitor Discovery
- Protein Degradation
- Drug Design
- Assay Development
- Phenotypic Screening
- Chemical Biology
- Organ-On-A-Chip
- Discovery Chemistry

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Drug Discovery
- Library Optimisation
- Phenotypic Screening
- Structure/Fragment Discovery
- Computational Design and Screening
- Structure/Fragment Discovery
- Preclinical Modelling
- Assay Development
- Organoid Platforms
- Automation
- Omics Technologies

Last year's delegates in numbers:
(From 2020's Discovery Series: Virtual)

FUNCTION
- 39% – Scientist / Academic
- 26% – Manager / Lead
- 23% – Director / Head Professor
- 12% – C-Level

SECTOR
- 52% – Industry
- 25% – Academics
- 23% – Sponsor / Vendor / Commercial

GEOGRAPHY
- 32% – Europe
- 21% – UK
- 20% – US
- 27% – Rest of World

Neuroscience Drug Development Europe: In-Person
June 2023 | Berlin, Germany

- **2-day Event**
- **In-Person Congress & Exhibition**
  (Supported Digitally)

A thorough 2-day event addressing emerging strategies for the drug development of Neuroscience and successful approaches for more targeted, precise, and transformative therapies to neurodegenerative and neuropsychiatric diseases.

Agenda at a Glance

Neuroscience Drug Development Europe: In-Person

Track 1:
Drug Discovery For Neurodegenerative Disease

- Target identification and validation approaches
- Stem cell technology to fuel drug discovery
- iPS cells for disease modelling and drug discovery
- Blood brain barrier in CNS drug discovery
- The role of informatics in CNS discovery

Track 2:
Therapeutic Strategies, Enabling Technologies & Biomarker Development

- Advancements and emerging trends in the application of technology in developing neurological treatments
- Neuroscience biomarker development - integration of biomarkers for diagnosis and patient stratification.
- Translational approaches for drug discovery
- Opportunities and challenges of designing targeted diagnostics and therapeutics

Who will be there?

300+ VPs, Directors & Senior Managers from leading pharma & biotech companies and academic institutions in the following fields and more

- Neuropharmacology
- Neuroscience Discovery
- Neuroimaging
- Neurodegenerative Diseases
- Biomarker Development
- Computational Neuroscience
- CNS Disease Research
- Organoid Development
- Organ On Chip

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Modelling and Simulation
- High Content & Phenotypic Screening
- Mouse Models
- Stem Cell Platform Technologies
- Contract Drug Discovery Research
- Imaging Technology
- Cell Line Development
- Neuroengineering Tools
- Biomarker Technologies

Last year's delegates in numbers:
(From 2020's Discovery Series: Virtual)

FUNCTION
- 39% – Scientist / Academic
- 26% – Manager / Lead
- 23% – Director / Head Professor
- 12% – C-Level

SECTOR
- 52% – Industry
- 25% – Academics
- 23% – Sponsor / Vendor / Commercial

GEOGRAPHY
- 32% – Europe
- 21% – UK
- 20% – US
- 27% – Rest of World

Discovery US: In-Person
November 2023 | Boston, USA

- **2-day Event**
- **In-Person Congress & Exhibition**
  (Supported Digitally)

Join and network with over 500 industry leaders at Discovery US: In-Person, where we will address the latest advancements in target identification, validation and HIT optimisation. The 2-day programme addresses drug discovery in new modalities such as protein degradation, and case studies on the integration of screening approaches in phenotypic and genomics-based discovery, Organ-on-a-chip and 3D modelling. Learn about key focus areas in drug design including AI in drug design: in chemical synthesis, target ID capabilities & lead identification/optimisation. Join our 2-day innovation showcase situated alongside the main programme, which aims to inspire growth and create collaboration opportunities for all who attend.

Agenda at a Glance

Discovery US: In-Person	
Drug Discovery Summit	**Drug Design & Medicinal Chemistry Summit**
Day One: Track 1: Identification And Validation Of Novel Targets For Next Generation Therapeutics Track 2: Animal And Disease Modelling, Organoid And Organ On The Chip Based Discovery Track 3: New Modalities And Challenging Targets: Targeted Protein Degradation And PROTAC **Day Two:** Track 1: Phenotypic & Target Based Discovery Approaches	**Day One:** Track 4: Computational Drug Design: AI In Chemical Synthesis, Target ID Capabilities, Lead Identification, Lead Optimisation, Measuring PK/PD & Prediction **Day Two:** Track 2: Hit Finding Technologies And Advancements Track 3: Part 1: Automation And Synthesis In Organic Chemistry Part 2: Molecular Drug Design And Med Chem: Innovations In Fragment & Structured Based Drug Discovery

Who will be there?

500+ VPs, Directors & Senior Managers from leading pharma & biotech companies and academic institutions in the following fields and more

- Structure-Based Drug Discovery
- Modelling and Simulation
- Target Validation
- Inhibitor Discovery
- Protein Degradation
- Molecular Drug Design
- AI/Machine Learning
- Computational Drug Design
- Chemical Biology
- Discovery Chemistry
- Lead Optimisation

Formal and informal meeting opportunities offer delegates the chance to discuss key solutions with leading service providers:

- Drug Discovery
- Library Optimisation
- Phenotypic Screening
- Structure/Fragment Discovery
- Computational Design and Screening
- Molecular Drug Design Tools
- Preclinical Modelling
- Assay Development
- Organoid Platforms
- Omics Technologies
- Automation

Previous year's delegates in numbers:
(From 2020's Discovery Series: Virtual)

FUNCTION
- 39% – Scientist / Academic
- 26% – Manager / Lead
- 23% – Director / Head Professor
- 12% – C-Level

SECTOR
- 52% – Industry
- 25% – Academics
- 23% – Sponsor / Vendor / Commercial

GEOGRAPHY
- 32% – Europe
- 21% – UK
- 20% – US
- 27% – Rest of World